Surna Inc (OTCMKTS: SRNA) is a manufacturer of environmental control and air sanitation systems for indoor cannabis cultivation facilities. The Boulder-based stock operates both in the US and Canada, providing water and energy-efficient solutions.
Thanks to Surna’s help, cannabis growers can meet the demands which successful cannabis cultivation requires. The company has a lot of experience although there have been failures along the way; even those have collectively have helped it to grow into its successful version.
Surna Stock Price Analysis
Surna’s price had a humble start, which is usually the case with greatest success stories. The company experienced massive growth in 2017 after having experienced some period of stability.
The growth extended to early last year, where the stock price was at $0.100. During that time the price grew almost four times to reach around $0.450. Things, however, got rough the entire last year with constant drops (still no sharp drops).
Earlier this year, the drop came to an end, and Surna saw some small surges; however, the damage was already done, the average was already dragged to $0.075. Until March, there was relative stability although there was a decline back to $0.06.
After that, the company’s stock increased again before getting on a continuous drop to where it is currently placed, at $0.0479.
An Overview of Surna Inc
With an array of experience in the industry, Surna has sharpened its expertise offering best solutions alongside teaching clients on ideal conditions for success as well as high-quality marijuana growth.
The company works with a variety of clients, be it an expert or a beginner in the field. The stock has had some ups and downs along the way just like most of the stocks in the industry, but it has gone past them successfully to the point that it’s now placed to take a hike.
Subsequently, Surna Inc. is engaged in the distribution of energy recovery units, chillers, and fan coils. It may seem that there’re no clear-cut updates to trigger a bounce, but technically the stock is on the right track for the big year 2019.
What Surna Inc Has Been Up To
The company had made changes to its management as the year started which clearly had an impact on the stock, seemingly indicating confidence in the stock which is crucial for the price surge. Besides, the new management is proving to propel the company forward in a manner that is required.
Also, not too long ago, Surna signed two project contracts for a combined value of around $4.7 million. The first contract is the new facility construction project for about $2.2 million for a 90,000 sq. Foot indoor marijuana facility built in the Midwest.
The second contract is a facility expansion project for $2.5 million for the 40,000 sq. Foot expansion of the fully operational as well as licensed indoor marijuana cultivation facility.
Another major update was the conversion of $2.76 million of the company’s 10% convertible promissory notes.
The Q4 2018 Report
Recently, Surna issued its Q4 2018 results, and one thing was impressive from the report which points to a bright future for the company. From the report, the revenue for 2018 went up by more than $2 million, compared to that of 2017.
The results meant the stock recorded a significant 33% growth despite the unfriendliness it experienced on the market. Besides, the net loss for 2018 was relatively smaller than that of Q4 2017, meaning the stock is just getting stronger each year.
What Now for Surna?
The company has already set a precise business and strategic plan for this year and 2020, which includes inter-related initiatives too. The plans include such as leveraging the stock brand name, positioning as well as messaging the stock in environmental controls management, and also offering a broader product alongside the service array.
For any indoor grow operation, the firm to look has to be Surna, and given the clear projections the company is working on, the stock is undoubtedly bound to get into an upward movement soon.
For the latest updates on SRNA and the hottest MJ stocks, sign up below!
Disclosure: We have no position in SRNA and have not been compensated for this article.
Forget APHA and ACB, Buy GTBIF and TCNNF
There are a lot of misconceptions going on when it comes to US legalization. Many investors are buying Aphria (APHA) and Aurora Cannabis (ACB) hoping to bank on what’s happening in the US. However, they are Canadian Licensed Producers and have no business in the US. Investors are buying them because they trade on the major exchanges, but that is the wrong move. The correct move is to buy the US multi-state operators like Green Thumb Industries (GTBIF) and Trulieve Cannabis (TCNNF).
On Election Day voters in New Jersey, Arizona, Montana and South Dakota voted to legalize recreational marijuana. South Dakota and Mississippi voters also approved measures to legalize medical marijuana.
There’s also the prospect of a more pot-friendly White House with President-elect Joe Biden. Vice Presidential Candidate Kamala Harris said at the debate a Biden administration would decriminalize marijuana at a federal level and expunge criminal records of people with marijuana-related offenses.
Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves.
Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rythm and The Feel Collection.
The company also owns and operates rapidly growing national retail cannabis stores called Rise™ and Essence. Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 96…
Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity
Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.
OTCMKTS:DECN Price Analysis
The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.
OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.
Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.
Decision Diagnostics bills itself…
Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?
CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.
The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.
Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.
CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.
Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.
CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment
CytoDyn’s lead drug candidate leronlimab (PRO 140)…